At a glance
ClinicalIndex Comparison RecordPhase 1Suspended· 20 target
Drug / intervention
AlloRxbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for the Treatment of Amyotrophic Lateral Sclerosis
The Foundation for Orthopaedics and Regenerative Medicine·interventional·Posted Aug 13, 2021·Updated Apr 17, 2025
In Brief
A Phase 1 clinical trial evaluating AlloRx for Amyotrophic Lateral Sclerosis. Suspended, targeting 20 participants across 1 site.
Signals
Trial is currently suspended
Detailed Summary
This trial will study the safety and efficacy of intrathecal injection of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of amyotrophic lateral sclerosis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesAntigua and Barbuda
Collaborators--
Timeline
Phase 1Suspended
2022202320242025202620272028
First PostedAug 2021
Enrollment StartDec 2025
TodayJul 2026
Primary CompletionSep 2028
First PostedAug 13, 2021
Enrollment StartDec 1, 2025
Primary CompletionSep 1, 2028
TodayJul 1, 2026
Enrollment to primary: 2.8 yearsPosted 4.9 years agoPrimary completion in 2.2 years
Interventions
AlloRxbiological
cultured allogeneic adult umbilical cord derived mesenchymal stem cells